Affibody Medical Investor Relations

Affibody Enters into Agreement with 3P Biopharmaceuticals for Production of ABY-035


May 27, 2019

Affibody Enters into Agreement with 3P Biopharmaceuticals for Production of ABY-035

Solna, Sweden, May 27, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced an agreement with 3P Biopharmaceuticals (“3P”) covering process development and GMP manufacturing of Affibody’s ABY-035 drug.
  • Affibody secures production capacity for ABY-035.
  • An important next step in the advancement of ABY-035 to late stage clinical development.

Ensuring large scale high quality production of our ABY-035 drug is a natural next step in our evolution as a company with the ambition to have development, manufacturing, and commercialization expertise”, said David Bejker, CEO of Affibody. “The work we have initiated together with 3P is important for us and we look forward to working with 3P.”

According to the agreement, 3P is responsible for transferring the process developed by Affibody to its facilities prior to execution of the first GMP manufacturing batches. 3P will also perform the process characterization and the process validation before entering the commercial batch manufacturing stage.

“We are very pleased to be working with Affibody on this project and to create a strong long-term partnership with them. We are sure that this is a mutually beneficial agreement.” says Dámaso Molero, General Manager at 3P Biopharmaceuticals. 

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that target psoriasis and rare Immunoglobulin G (IgG)-mediated autoimmune diseases. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

In addition, to its portfolio of innovative drug projects the company offers the half-life extension technology, Albumod™, for outlicensing. Affibody AB is a holding of Patricia Industries. For more information on Affibody, please visit the company’s website at